Implications of identifying the recently defined members of the Staphylococcus aureus complex S. argenteus and S. schweitzeri: a position paper of members of the ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Implications of identifying the recently defined members of the Staphylococcus aureus complex S. argenteus and S. schweitzeri : a position paper of members of the ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS). / Becker, K.; Schaumburg, F.; Kearns, A.; Larsen, A. R.; Lindsay, J. A.; Skov, R. L.; Westh, H.
I: Clinical Microbiology and Infection, Bind 25, Nr. 9, 2019, s. 1064-1070.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Implications of identifying the recently defined members of the Staphylococcus aureus complex S. argenteus and S. schweitzeri
T2 - a position paper of members of the ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)
AU - Becker, K.
AU - Schaumburg, F.
AU - Kearns, A.
AU - Larsen, A. R.
AU - Lindsay, J. A.
AU - Skov, R. L.
AU - Westh, H.
PY - 2019
Y1 - 2019
N2 - Background: Staphylococcus argenteus and Staphylococcus schweitzeri, previously known as divergent Staphylococcus aureus clonal lineages, have been recently established as novel, difficult-to-delimit, coagulase-positive species within the S. aureus complex. Methicillin-resistant strains of S. argenteus are known from Australia and the UK. Knowledge of their epidemiology, medical significance and transmission risk is limited and partly contradictory, hampering definitive recommendations. There is mounting evidence that the pathogenicity of S. argenteus is similar to that of ‘classical’ S. aureus, while as yet no S. schweitzeri infections have been reported. Aim: To provide decision support on whether and how to distinguish and report both species. Sources: PubMed, searched for S. argenteus and S. schweitzeri. Content: This position paper reviews the main characteristics of both species and draws conclusions for microbiological diagnostics and surveillance as well as infection prevention and control measures. Implications: We propose not distinguishing within the S. aureus complex for routine reporting purposes until there is evidence that pathogenicity or clinical outcome differ markedly between the different species. Primarily for research purposes, suitably equipped laboratories are encouraged to differentiate between S. argenteus and S. schweitzeri. Caution is urged if these novel species are explicitly reported. In such cases, a specific comment should be added (i.e. ‘member of the S.aureus complex’) to prevent confusion with less- or non-pathogenic staphylococci. Prioritizing aspects of patient safety, methicillin-resistant isolates should be handled as recommended for methicillin-resistant Staphylococcus aureus (MRSA). In these cases, the clinician responsible should be directly contacted and informed by the diagnosing microbiological laboratory, as they would be for MRSA. Research is warranted to clarify the epidemiology, clinical impact and implications for infection control of such isolates.
AB - Background: Staphylococcus argenteus and Staphylococcus schweitzeri, previously known as divergent Staphylococcus aureus clonal lineages, have been recently established as novel, difficult-to-delimit, coagulase-positive species within the S. aureus complex. Methicillin-resistant strains of S. argenteus are known from Australia and the UK. Knowledge of their epidemiology, medical significance and transmission risk is limited and partly contradictory, hampering definitive recommendations. There is mounting evidence that the pathogenicity of S. argenteus is similar to that of ‘classical’ S. aureus, while as yet no S. schweitzeri infections have been reported. Aim: To provide decision support on whether and how to distinguish and report both species. Sources: PubMed, searched for S. argenteus and S. schweitzeri. Content: This position paper reviews the main characteristics of both species and draws conclusions for microbiological diagnostics and surveillance as well as infection prevention and control measures. Implications: We propose not distinguishing within the S. aureus complex for routine reporting purposes until there is evidence that pathogenicity or clinical outcome differ markedly between the different species. Primarily for research purposes, suitably equipped laboratories are encouraged to differentiate between S. argenteus and S. schweitzeri. Caution is urged if these novel species are explicitly reported. In such cases, a specific comment should be added (i.e. ‘member of the S.aureus complex’) to prevent confusion with less- or non-pathogenic staphylococci. Prioritizing aspects of patient safety, methicillin-resistant isolates should be handled as recommended for methicillin-resistant Staphylococcus aureus (MRSA). In these cases, the clinician responsible should be directly contacted and informed by the diagnosing microbiological laboratory, as they would be for MRSA. Research is warranted to clarify the epidemiology, clinical impact and implications for infection control of such isolates.
KW - Diagnostics
KW - Epidemiology
KW - Infection control
KW - MRSA
KW - Pathogenicity
KW - Prevention
KW - Recommendation
KW - Staphylococcus argenteus
KW - Staphylococcus aureus
KW - Staphylococcus schweitzeri
U2 - 10.1016/j.cmi.2019.02.028
DO - 10.1016/j.cmi.2019.02.028
M3 - Review
C2 - 30872103
AN - SCOPUS:85063439443
VL - 25
SP - 1064
EP - 1070
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
SN - 1198-743X
IS - 9
ER -
ID: 235920368